Myricericacid B is a potent HIV-1 entry inhibitor targeting gp41 and can serve as a lead compound for novel anti-HIV-1 drug development. It scavenges DPPH free radicals with an IC50 value of 21.8 µM and inhibits aromatase activity with an IC50 value of [incomplete data].